News
8d
MotorTrend on MSNThis Minty Nissan 240SX Looks Like a Show Car, But Is Actually a Full-Blown Drift MachineY our parents consistently warned you never to judge a book by its cover, and that little nugget of parental wisdom is ...
Vertex Rail Technologies opened in Wilmington in 2014 with promises of over 1,300 jobs and a $60 million investment. Despite initial optimism and orders, the company faced setbacks including ...
Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain ...
Cheng Xin / Getty Images Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped. The biotech firm also posted a decline in sales outside the U.S. because of ...
Vertex Pharmaceuticals reported disappointing Q1 revenue and earnings. The company also revealed it is temporarily pausing part of a phase 1/2 study of experimental cystic fibrosis drug VX-522 ...
Vertex Pharmaceuticals misses analyst estimates on the top and bottom lines in the first quarter. Vertex raises its full-year 2025 revenue guidance to a range of $11.85 billion to $12 billion ...
You can reach Jason on Signal at JasonMast.05. Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic ...
Google Cloud’s latest enhancements to Vertex AI and the Gemini model family offer businesses a comprehensive solution for building, deploying, and managing AI applications with unprecedented ...
Vertex will not advance VX-264 trials after the study failed to meet efficacy endpoints, despite being generally safe and well tolerated. Zimislecel, Vertex’s islet cell therapy, remains on ...
Vertex Pharmaceuticals (Nasdaq: VRTX) specialises in treatments for rare diseases. It has eight approved medicines on the market. Seven of these are medicines for various types of cystic fibrosis ...
Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed for now on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug ...
Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results